"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"

Summary

This is a multi-center, double-masked, randomized, active-controlled, parallel-group, efficacy and safety study that will enroll 386 participants at up to six clinical sites. Participants with ocular redness will be randomized to receive either brimonidine tartrate ophthalmic solution 0.025%, preservative-free formulation, or Lumify® (brimonidine tartrate ophthalmic solution 0.025%). Participants will be treated with study drug for approximately 4 weeks.

Timeline

Start

2022-05-13

Primary completion

2022-11-23

Completion

2022-11-23

Publications

• Toyos M, DiVito M, Messmer EM, McGee S, Peterson J, Patel A, Pattar G, Evans DG, Vollmer PM, Wesley G. A Multicenter Randomized Double-Masked Study Comparing Preservative-free Brimonidine Tartrate Ophthalmic Solution 0.025% with LUMIFY(R) 0.025% for Ocular Redness in Adults. Ophthalmol Ther. 2025 Sep;14(9):2283-2299. doi: 10.1007/s40123-025-01194-z. Epub 2025 Jul 25.

Drugs

Indications